YMTX Insider Trading
Notice: This stock is marked as potentially delisted. It may not be actively trading.
Insider Ownership Percentage: 12.45%
Insider Buying (Last 12 Months): $0.00
Insider Selling (Last 12 Months): $0.00
Yumanity Therapeutics Share Price & Price History
Current Price: $0.00
Price Change: +0.30 (1.20%)
As of 10/24/2024 01:00 AM ET
Yumanity Therapeutics Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
| 12/2/2022 | Michael D Wyzga | Insider | Sell | 3,116 | $1.69 | $5,266.04 | 13,997 |  |
| 12/2/2022 | Richard Peters | CEO | Sell | 10,890 | $1.69 | $18,404.10 | 90,028 | |
Yumanity Therapeutics Institutional Trading History
| Reporting Date | Hedge Fund | Shares Held | Market Value | % of Portfolio | Quarterly Change in Shares | Ownership in Company | Details |
|---|
| 8/12/2022 | Ikarian Capital LLC | 104,392 | $0.19M | 0.0% | -55.8% | 0.962% |  |
| 8/1/2022 | Monaco Asset Management SAM | 50,000 | $91K | 0.0% | N/A | 0.461% | |
| 2/10/2022 | Acadian Asset Management LLC | 75,928 | $0.22M | 0.0% | +272.7% | 0.737% | |
| 11/17/2021 | Altium Capital Management LP | 196,000 | $2.02M | 0.5% | +58.5% | 1.902% | |
| 11/16/2021 | Bain Capital Public Equity Management II LLC | 27,972 | $0.29M | 0.0% | -8.3% | 0.271% | |
| 11/15/2021 | Sphera Funds Management LTD. | 75,836 | $0.78M | 0.1% | -34.2% | 0.736% | |
| 11/15/2021 | Ovata Capital Management Ltd | 18,700 | $0.19M | 0.1% | N/A | 0.181% | |
| 11/15/2021 | Ensign Peak Advisors Inc | 33,840 | $0.35M | 0.0% | N/A | 0.328% | |
| 11/12/2021 | Renaissance Technologies LLC | 35,919 | $0.37M | 0.0% | N/A | 0.349% | |
| 11/12/2021 | Stonepine Capital Management LLC | 481,692 | $4.97M | 2.3% | +9.0% | 4.674% | |
| 11/12/2021 | Jump Financial LLC | 10,300 | $0.11M | 0.0% | N/A | 0.100% | |
| 11/9/2021 | BlackRock Inc. | 69,905 | $0.72M | 0.0% | +6.9% | 0.678% | |
Data available starting January 2016
Yumanity Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the research and development of treatments for neurodegenerative diseases caused by protein misfolding. The company focuses on discovering disease-modifying therapies to treat neurodegenerative diseases, including Parkinson's disease, dementia with Lewy bodies, multiple system atrophy, amyotrophic lateral sclerosis, and frontotemporal lobar degeneration. Its lead program is YTX-7739, a novel small molecule that is in Phase I clinical trial for the treatment of Parkinson's disease and related disorders of a-synuclein. The company is also developing YTX-9184, which is in preclinical studies to treat neurological disorders. Yumanity Therapeutics Inc. has a license and research collaboration agreement with Merck Sharp & Dohme Corp. The company was founded in 2014 and is headquartered in Boston, Massachusetts.
Read More on Yumanity Therapeutics
Today's Range
Now: N/A
52 Week Range
Now: N/A
Volume
6,790 shs
Average Volume
473,083 shs
Market Capitalization
$7.46 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
0.32
